Multicomponent diversity oriented synthesis of multivalent glycomimetics containing hexafluorovaline

Sugars in Multicomponent Reactions: A Toolbox for Diversity-Oriented Synthesis

Multicomponent reactions (MCRs) cover strategically employed chemical transformations that incorporate three or more reactants in one pot leading to a functionalized final product. Thus, it is an ideal tool to achieve high levels of complexity, diversity, yields of desired products, atom economy, and reduced reaction times. Sugars belong to the class of naturally occurring compounds with fascinating applications in the field of drug discovery due to the presence of various hydroxy groups and well-defined stereochemistry. However, their potential in MCRs has been realized only recently. This account describes recent advances in the synthesis of sugar-derived heterocycles synthesized by MCRs. We hope to encourage the synthetic and medicinal chemistry community to apply this powerful MCR chemistry to generate novel glycoconjugate challenges.

1 Introduction

2 Synthesis of Various Functionalized Sugar Compounds

2.1 Passerini and Ugi Multicomponent Reactions

2.2 Petasis Reaction

2.3 Hantzsch Reaction

2.4 Domino Ferrier–Povarov Reaction

2.5 Marckwald Reaction

2.6 Groebke–Blackburn–Bienaymé (GBB) Reaction

2.7 Prins–Ritter Reaction

2.8 Debus–Radziszewski Imidazole Synthesis Reaction

2.9 Mannich Reaction

2.10 A3-Coupling Reaction

2.11 [3+2]-Cycloaddition Reactions

2.12 Miscellaneous Reactions

3 Conclusion

Recent Advances in the Synthesis of Hydantoins: The State of the Art of a Valuable Scaffold

The review highlights the hydantoin syntheses presented from the point of view of the preparation methods. Novel synthetic routes to various hydantoin structures, the advances brought to the classical methods in the aim of producing more sustainable and environmentally friendly procedures for the preparation of these biomolecules, and a critical comparison of the different synthetic approaches developed in the last twelve years are also described. The review is composed of 95 schemes, 8 figures and 528 references for the last 12 years and includes the description of the hydantoin-based marketed drugs and clinical candidates.